Skip to main content
. 2015 Nov 7;108(1):djv292. doi: 10.1093/jnci/djv292

Figure 4.

Figure 4.

Cumulative risk and benefit proportions for studies in non–US Food and Drug Administration–approved indications. All events were classified by report authors as probably or definitely drug related. Dates are based on trial closure. ORR = overall response rate.